The Female Health Company / Veru Healthcare Names Matthew Gosnell, Ph.D., as Senior Vice President of Manufacturing, Preclini...
February 16 2017 - 8:30AM
The Female Health Company / Veru Healthcare (NASDAQ:FHCO) today
announced the appointment of Matthew C. Gosnell, Ph.D., as Senior
Vice President of Manufacturing, Preclinical and Pharmaceutical
Development, effective February 15, 2017.
Gosnell has a Ph.D. in analytical chemistry and more than 20
years of experience in pharmaceutical manufacturing, development
and sourcing. His experience ranges from preclinical and
investigational new drugs (INDs) through 505(b)(2) and 505(b)(1)
New Drug Applications (NDAs) and commercialization. He will
be responsible for identifying clinical and commercial
manufacturing partners, chemical synthesis and process scale up
development, development and clinical trial materials manufacturing
and processes, documentation and submissions related to chemistry,
manufacturing and control.
“An accomplished scientist and drug developer, Dr. Gosnell
brings hands-on experience in strategic planning and execution of
process development and manufacturing of both early and late stage
drug products,” said Mitchell Steiner, M.D., President and Chief
Executive Officer of The Female Health Company / Veru
Healthcare. “He has extensive knowledge and expertise in
leading multiple projects in various stages of development and
identifying and managing new drug manufacturing sites for clinical
development and commercial supply. Over his career, Dr.
Gosnell has made significant contributions to several 505(b)(2) and
505(b)(1) NDAs including Celebrex®, Risperdal® Consta® and
Vivitrol® and served in senior level positions with GTx, Alkermes,
Pharmacia, McNeil Specialty Products (a division of Johnson &
Johnson) and Miles (a unit of Bayer AG).”
Prior to joining the Company, Dr. Gosnell served as Senior
Director, Product Development and Analytical Sciences for GTx,
Inc., where he advanced multiple drug candidates into successive
clinical stages of development. Earlier in his career, he was
Director, Quality Technical Services (Analytical Development and
Stability) for Alkermes, Inc., Analytical Team Leader for Pharmacia
Research and Development and Senior Scientist at McNeil Specialty
Products Company. Dr. Gosnell began his career as Scientist
with Miles, Inc., after earning a Doctoral degree in Analytical
Chemistry from Oklahoma State University and a Bachelor of Science
degree in Chemistry and Mathematics-Computer Science from
Manchester College.
About The Female Health Company / Veru
HealthcareThe Female Health Company / Veru Healthcare is a
pharmaceutical and medical device company, with a focus on the
development and commercialization of pharmaceuticals that qualify
for the FDA's 505(b)(2) accelerated regulatory approval pathway as
well as the 505(b)(1) pathway. The Company does business both
as "Veru Healthcare" and as "The Female Health Company" and is
organized as follows:
- Veru Healthcare manages the Pharmaceuticals Division, which
develops and commercializes pharmaceutical products for men's and
women's health and oncology.
- Veru Healthcare manages the Consumer Health / Medical Devices
Division, which is focused on commercializing sexual healthcare
products and devices for the consumer market, including the
Company's FC2 Female Condom® in the consumer health products sector
and PREBOOST® medicated individual wipe, which is a male genital
desensitizing drug product that helps in the prevention of
premature ejaculation.
- The Female Health Company manages the Global Public Health
Division, which is focused on the global public health sector FC2
business. This division markets the Company’s Female Condom
(FC2) to entities, including ministries of health, government
health agencies, U.N. agencies, nonprofit organizations and
commercial partners, that work to support and improve the lives,
health and well-being of women around the world.
More information about the Female Health Company and its
products can be found at www.femalehealth.com,
www.veruhealthcare.com and www.femalecondom.org. For
corporate and investor-related information about the Company,
please visit www.FHCinvestor.com.
Contact:
Kevin Gilbert
312-366-2633
Veru (NASDAQ:VERU)
Historical Stock Chart
From Mar 2024 to Apr 2024
Veru (NASDAQ:VERU)
Historical Stock Chart
From Apr 2023 to Apr 2024